NTK1 Stock Chart & Stats
€0.54
>-€0.01(-0.91%)
At close: 4:00 PM EDT
€0.54
>-€0.01(-0.91%)
Day’s Range― - ―
52-Week Range€0.41 - €0.63
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€17.49M
Enterprise Value€16.47
Total Cash (Recent Filing)€511.00K
Total Debt (Recent Filing)€2.60M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding27,967,531
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio5.74
Price to Book (P/B)1.04
Price to Sales (P/S)5.52
P/FCF Ratio-12.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€39.62K
Bulls Say, Bears Say
Bulls Say
Focused Life‑sciences Investment ModelNetScientific’s specialist mandate in early‑stage life sciences creates durable advantages: targeted deal flow, sector expertise and active portfolio support increase probability of value-creating exits. A focused strategy helps allocate scarce capital to high-conviction opportunities and build long-term relationships in a niche market.
Improving Revenue Growth TrendConsistent revenue acceleration signals portfolio maturation or growing realized income, which is a durable sign the business model is progressing toward commercialization. Sustained top-line growth improves the potential for operational leverage, reduces reliance on financing, and supports a path toward self-funding over multiple quarters.
Historically Conservative Leverage And Equity CushionA historically low debt profile and meaningful equity base provide financial resilience to absorb valuation swings and operating losses. This structural cushion gives the firm runway to support portfolio companies, pursue follow-on investments, and manage exits without immediate distress financing in normal market conditions.
Bears Say
Persistent Negative Operating Cash FlowSustained negative operating and free cash flow is a structural weakness: the company cannot self-fund operations or new investments from internal cash and likely depends on external capital or asset disposals. Over months this raises dilution and execution risk if exit cadence or fundraising capacity falters.
Deep And Sustained Operating LossesLarge recurring operating losses indicate the cost base remains misaligned with current revenue scale. Persistently negative EBIT/EBITDA undermines long-term sustainability, forces reliance on balance sheet or capital markets for funding, and limits flexibility to invest in higher-return opportunities without eroding shareholder value.
Eroding Equity And Rising Debt In 2025Declining equity coupled with a recent rise in debt reduces financial flexibility and increases solvency risk if losses continue. Structurally, this limits the company’s ability to fund follow‑on investments or weather valuation shocks without dilutive capital raises or higher-cost borrowing, affecting long-term strategy execution.
NetScientific News
NTK1 FAQ
What was NetScientific PLC’s price range in the past 12 months?
NetScientific PLC lowest stock price was €0.41 and its highest was €0.63 in the past 12 months.
What is NetScientific PLC’s market cap?
NetScientific PLC’s market cap is €17.49M.
When is NetScientific PLC’s upcoming earnings report date?
NetScientific PLC’s upcoming earnings report date is Sep 24, 2026 which is in 52 days.
How were NetScientific PLC’s earnings last quarter?
Currently, no data Available
Is NetScientific PLC overvalued?
According to Wall Street analysts NetScientific PLC’s price is currently Overvalued.
Does NetScientific PLC pay dividends?
NetScientific PLC does not currently pay dividends.
What is NetScientific PLC’s EPS estimate?
NetScientific PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NetScientific PLC have?
NetScientific PLC has 27,967,531 shares outstanding.
What happened to NetScientific PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NetScientific PLC?
Currently, no hedge funds are holding shares in DE:NTK1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NetScientific PLC
EMV Capital plc operates as a venture capital firm, primarily targeting investments across the full spectrum of early-stage funding, from seed rounds through to mid-stage and growth capital. Its investment mandate spans diverse high-growth sectors, including sustainability, life science, technology, transformative biomedical, deep tech, semiconductors, industrials, robotics, and artificial intelligence. The firm also places a strong emphasis on healthcare technologies, particularly digital health, diagnostics, and therapeutics, with a specific focus on ventures that enhance the lives and health outcomes of individuals battling chronic illnesses. Within digital health, core interests lie in data analytics, advanced wearable devices, and other related technologies. Geographically, EMV Capital seeks opportunities within developed European markets, including its home base in the United Kingdom, as well as the United States. While typical investment sizes reach up to £15 million (approximately $20.32 million), the firm retains the flexibility to commit larger sums. A strategic preference is to secure a controlling stake in key subsidiary companies, with investments primarily executed via its balance sheet. Established in 2008, EMV Capital plc operates from its headquarters in London, UK, with an additional presence in Beaconsfield.